11 hasil untuk "Puneet Kumar"
Menampilkan 1–11 · 0,17 detik · RSS
-
Artikel Jurnal Teks lengkap
Antigenicity of a Bacterially Expressed Triple Chimeric Antigen of Plasmodium falciparum AARP, MSP-3 11 and MSP-1 19 : PfAMSP-Fu 35
Development of fusion chimeras as potential vaccine candidates is considered as an attractive strategy to generate effective immune responses to more than one antigen using a single construct. Here, we described the design, production, purification and antigenicity of a fusion chimera…
-
Artikel Jurnal Teks lengkap
HIV Seroprevalence among Tuberculosis Patients in India, 2006–2007
Background: Little information exists regarding the burden of HIV among tuberculosis patients in India, and no population-based surveys have been previously reported. A community-based HIV prevalence survey was conducted among tuberculosis patients treated by the national tuberculosis control…
-
Artikel Jurnal Teks lengkap
Tuberculosis Management Practices of Private Practitioners in Pune Municipal Corporation, India
Background: Private Practitioners (PP) are the primary source of health care for patients in India. Limited representative information is available on TB management practices of Indian PP or on the efficacy of India’s Revised National Tuberculosis Control Programme (RNTCP) to improve the quality of…
-
Artikel Jurnal Teks lengkap
Sputum Smear Microscopy at Two Months into Continuation-Phase: Should It Be Done in All Patients with Sputum Smear-Positive Tuberculosis?
Background: The Revised National Tuberculosis Control Program (RNTCP) of India recommends follow-up sputum smear examination at two months into the continuation phase of treatment. The main intent of this (mid-CP) follow-up is to detect patients not responding to treatment around two-three months…
-
Artikel Jurnal Teks lengkap
From Where Are Tuberculosis Patients Accessing Treatment in India? Results from a Cross-Sectional Community Based Survey of 30 Districts
Background: Tuberculosis (TB) notification in India by the Revised National TB Control Programme (RNTCP) provides information on TB patients registered for treatment from the programme. There is limited information about the proportion of patients treated for TB outside RNTCP and where these…
-
Artikel Jurnal Teks lengkap
Source of Previous Treatment for Re-Treatment TB Cases Registered under the National TB Control Programme, India, 2010
Background: In 2009, nearly half (289,756) of global re-treatment TB notifications are from India; no nationally-representative data on the source of previous treatment was available to inform strategies for improvement of initial TB treatment outcome. Objectives: To assess the source of previous…
-
Artikel Jurnal Teks lengkap
Characteristics and Programme-Defined Treatment Outcomes among Childhood Tuberculosis (TB) Patients under the National TB Programme in Delhi
Background: Childhood tuberculosis (TB) patients under India's Revised National TB Control Programme (RNTCP) are managed using diagnostic algorithms and directly observed treatment with intermittent thrice-weekly short-course treatment regimens for 6–8 months. The assignment into pre-treatment…
-
Artikel Jurnal Teks lengkap
Factors Associated with Delays in Treatment Initiation after Tuberculosis Diagnosis in Two Districts of India
Background: Excessive time between diagnosis and initiation of tuberculosis (TB) treatment contributes to ongoing TB transmission and should be minimized. In India, Revised National TB Control Programme (RNTCP) focuses on indicator start of treatment within 7 days of diagnosis for patients with…
-
Artikel Jurnal Teks lengkap
Can Follow-Up Examination of Tuberculosis Patients Be Simplified? A Study in Chhattisgarh, India
Background: Each follow-up during the course of tuberculosis treatment currently requires two sputum examinations. However, the incremental yield of the second sputum sample during follow-up of different types of tuberculosis patients has never been determined precisely. Objectives: To assess the…
-
Artikel Jurnal Teks lengkap
Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175
Background: A phase I randomised, controlled, single blind, dose escalation trial was conducted to evaluate safety and immunogenicity of JAIVAC-1, a recombinant blood stage vaccine candidate against Plasmodium falciparum malaria, composed of a physical mixture of two recombinant proteins…